Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. - sprookjes - yvandenbroek - TriplyDB

Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.

Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.

http://www.wikidata.org/entity/Q42243136

about

Efficacy of Second Generation Direct-Acting Antiviral Agents for Treatment Naïve Hepatitis C Genotype 1: A Systematic Review and Network Meta-Analysis New approaches in the treatment of hepatitis C Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals Modulation of host lipid metabolism by hepatitis C virus: Role of new therapies Emerging therapies for hepatitis C Hepatitis C virus: A global view Sofosbuvir/velpatasvir: A promising combination Interferon therapy in hepatitis C leading to chronic type 1 diabetes Assessing Hepatitis C Burden and Treatment Effectiveness through the British Columbia Hepatitis Testers Cohort (BC-HTC): Design and Characteristics of Linked and Unlinked Participants High-resolution hepatitis C virus subtyping using NS5B deep sequencing and phylogeny, an alternative to current methods Four weeks of paritaprevir/ritonavir/ombitasvir plus dasabuvir encountering dengue fever resulted in sustained virological response in an HCV patient: A case report.Hepatitis C treatment: where are we now?HCV Council--critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscape Clinical efficacy and tolerability of direct-acting antivirals in elderly patients with chronic hepatitis C.Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world?Hepatitis C drugs: the end of the pegylated interferon era and the emergence of all-oral interferon-free antiviral regimens: a concise review Beyond interferon: rationale and prospects for newer treatment paradigms for chronic hepatitis C.Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America.The evolution of three decades of antiretroviral therapy: challenges, triumphs and the promise of the future.Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in U.S. incarcerated populations: a cost-effectiveness analysis Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection.Molecular diagnostics in the management of chronic hepatitis C: key considerations in the era of new antiviral therapies.Should NS5A inhibitors serve as the scaffold for all-oral anti-HCV combination therapies?Association of hepatitis C viral infection with incidence and progression of chronic kidney disease in a large cohort of US veterans.Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study Direct-acting Antiviral Agents for the Treatment of Chronic Hepatitis C Virus Infection.Randomized Trial Evaluating the Impact of Ribavirin Mono-Therapy and Double Dosing on Viral Kinetics, Ribavirin Pharmacokinetics and Anemia in Hepatitis C Virus Genotype 1 Infection Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir.Exposure-Safety Response Relationship for Ombitasvir, Paritaprevir/Ritonavir, Dasabuvir, and Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: Analysis of Data from Five Phase II and Six Phase III Studies.Impact of hepatitis C status on 20-year mortality of patients with substance use disorders.Characterizing the Burden of Hepatitis C Infection Among Entrants to Pennsylvania State Prisons, 2004 to 2012.Drug Interactions with the Direct-Acting Antiviral Combination of Ombitasvir and Paritaprevir-Ritonavir Population Pharmacokinetics of Paritaprevir, Ombitasvir, Dasabuvir, Ritonavir, and Ribavirin in Patients with Hepatitis C Virus Genotype 1 Infection: Combined Analysis from 9 Phase 1b/2 Studies Short interferon and ribavirin treatment for HCV genotype 2 or 3 infection: NORDynamIC trial and real-life experience.Hepatitis B and C in pregnancy: a review and recommendations for care.High adherence to all-oral directly acting antiviral HCV therapy among an inner-city patient population in a phase 2a study.Pharmacokinetics and tolerability of paritaprevir, a direct acting antiviral agent for hepatitis C virus treatment, with and without ritonavir in healthy volunteers.Evaluation of Drug-Drug Interactions between Direct-Acting Anti-Hepatitis C Virus Combination Regimens and the HIV-1 Antiretroviral Agents Raltegravir, Tenofovir, Emtricitabine, Efavirenz, and Rilpivirine Men with severe hemophilia in the United States: birth cohort analysis of a large national database Drug-Drug Interactions Between the Anti-Hepatitis C Virus 3D Regimen of Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and Eight Commonly Used Medications in Healthy Volunteers.

P2860

Q26771458-1BD0D59F-2F4B-4FA3-9712-9D7E2B92E62E Q26773271-3CE497EF-76C2-4D76-B74D-3C64F34B6F75 Q26773321-B4B8E3DC-EC61-492E-88B2-EC3C6B9D98E2 Q26782009-F9B866D9-7845-4C65-B32D-045B6619F572 Q26853642-9A2944B1-7997-436B-A617-48E46DF6F1B5 Q26862531-501290FE-C5A2-4F0B-BF3E-D8E6C82D1EE2 Q27468954-FA2D7715-E12D-47E3-B551-5FEEF8A6D72A Q28080876-A995F109-7435-44FD-82B3-1B8821E62FD4 Q28550601-357E1FA8-1541-4070-A4D2-55AE4997CF62 Q28652352-FB76922D-BAE8-4C4B-82C2-FABE5E42FBA2 Q30368260-479E9E98-713E-4388-B9A3-F39039B92290 Q30378509-1AAAFC03-6F01-4AB1-B688-433E55F9AA97 Q31012317-C7D796D3-6281-4CB1-AE0E-7E94D2F3F205 Q33440436-EDEBF405-2CA7-4455-916B-57BB0E73E6C5 Q34424151-FAED5992-8209-4BF4-9E56-570CE95AA70C Q34439125-CCC423DA-1135-4998-BEA8-50072C5A33DD Q34725990-471FC82D-8371-454F-AC30-47B10F630E7A Q34736194-44FB8CCE-417E-4AC2-A483-CB966974CB42 Q35023687-7B2D3536-9182-4ED1-B9F4-89274CCCBB7E Q35037688-E9F03C35-A6E8-4D05-80B2-3ABBFA561FCE Q35044909-53B3957B-1254-4792-A061-7659EBB5A258 Q35263756-B6CA0944-0B0B-4A95-AFD0-0DDCE6035D1C Q35491398-ECF926CA-DD15-4C5A-AE86-41DA5B699BA5 Q35528192-E358EE88-7D76-430A-B02B-A5F92AC87B71 Q35592257-96F12A20-645F-4236-BC0F-65579F4E7181 Q35905985-A62657CE-6208-4A84-943D-103FF9881C03 Q36014286-85020122-C69B-4DB0-91F9-47F62A126588 Q36052284-FBA457B3-02B9-4D45-A151-CCD0FDAF7AB6 Q36335281-30D7B6C9-5B83-4D45-874B-A4A8A087137D Q36354119-039A1239-69BD-48C3-830F-D2C09CE772F8 Q36382409-7A0CAE71-D1A7-436E-9CE4-02B7AF66E648 Q36438920-716CDD36-4527-4F99-A6B3-8B5EAE22A6AD Q36445132-12D3AC43-FBEE-4F82-B2B8-58FE3D7EDDED Q36519135-A6500525-B0E3-4A41-99C5-8483E2D59CB8 Q36649138-0E89E2C0-1228-4AED-AD4A-23F5158DF0B8 Q36651317-1DA0A57A-C63F-4A52-8F92-A2126C2CFFE8 Q36806650-AEFC2BCD-636D-4BD6-903B-9FB180B1839D Q36888008-4F91935E-95E9-4D8D-84F0-8BABAA0A16EA Q37015686-A0FA33C8-15B3-4A48-B223-548499749D89 Q37067118-AFED0EAD-8F50-48E4-8700-9949203B0794

P2860

Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.

http://www.wikidata.org/entity/Q42243136

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.

@en

Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.

@nl

type

label

Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.

@en

Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.

@nl

prefLabel

Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.

@en

Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.

@nl

P1433

Q42243136-B5F5C973-0531-4168-9F3C-F485374430D2

P1476

Q42243136-165A19C2-078C-4C32-8FBF-AD0E39C27A40

P2093

Q42243136-0FBDE47D-594D-4974-8645-96CA2BC51BB3

Q42243136-10D3387F-C45C-48CD-9417-8A2C4346D468

Q42243136-217BA401-95A3-4A97-805A-F4C796D8A3F4

Q42243136-73B786B9-156B-428E-8782-6837BD6F3130

Q42243136-887E50D6-A75D-49BC-8643-E0F7CF6D95F8

Q42243136-89FF53A7-3456-465F-A452-6C90F5EE55A2

Q42243136-8A36032A-A709-4AF7-9DE4-B7162196CAAF

Q42243136-B6E8AD3D-00F9-4A40-B890-DEAE9A9DF172

Q42243136-C09AE67A-3713-4BF0-944D-D52552436C59

Q42243136-C3CD8592-4A31-4494-8B49-AE0892DFAF66

P304

Q42243136-E5E509AF-A257-4E1F-A76A-558CC4A4F8E9

P31

Q42243136-CD02871B-D86B-410F-8505-BFC60CA99065

P356

Q42243136-13E2ECE6-ADBD-4C2C-B97A-E0852B09BC7A

P407

Q42243136-1340CE63-80CE-483B-A312-5A5590EC2487

P433

Q42243136-30D71520-9A63-4D4A-BCBC-DC285F00ADD8

P478

Q42243136-A8B4AF5D-5F58-4768-AF86-3AB2D610041F

P50

Q42243136-18D552FF-352F-41BC-ADDC-59E991B731B3

Q42243136-AA85E212-66D3-4164-9F1D-62B6DDCF17BC

Q42243136-DD885E58-DA18-4585-BABA-3AE0A6744C41

P577

Q42243136-ED0EE00E-1A17-4312-AE99-7BB424D949F7

P698

Q42243136-3B96CD0C-5387-478D-8675-A235BD0898A1

P356

P1433

The New England Journal of Medicine

P1476

Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.

@en

P2093

Amit Khatri

http://www.w3.org/2001/XMLSchema#string

Barry Bernstein

http://www.w3.org/2001/XMLSchema#string

Daniel E Cohen

http://www.w3.org/2001/XMLSchema#string

David R Nelson

http://www.w3.org/2001/XMLSchema#string

Eric Lawitz

http://www.w3.org/2001/XMLSchema#string

George Liossis

http://www.w3.org/2001/XMLSchema#string

Graham R Foster

http://www.w3.org/2001/XMLSchema#string

Gregory T Everson

http://www.w3.org/2001/XMLSchema#string

Kris V Kowdley

http://www.w3.org/2001/XMLSchema#string

Lois Larsen

http://www.w3.org/2001/XMLSchema#string

P304

222-232

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1306227

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

370

http://www.w3.org/2001/XMLSchema#string

P50

Tami Pilot-Matias

P577

2014-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24428468

http://www.w3.org/2001/XMLSchema#string